225. Congenital nephrogenic diabetes insipidus
12 clinical trials, 45 drugs (DrugBank: 17 drugs), 30 drug target genes, 63 drug target pathways
Searched query = "Congenital nephrogenic diabetes insipidus", "Hereditary nephrogenic diabetes insipidus", "Nephrogenic diabetes insipidus"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2006-001202-84-NL (EUCTR) | 01/02/2007 | 31/01/2007 | Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDI | Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDI | Lithium-induced Nephrogenic Diabetes Insipidus MedDRA version: 9.1;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic | Trade Name: Midamor Product Name: Amiloride Trade Name: Hydrochloorthiazide Product Name: hydrochloorthiazide | Radboud University Nijmegen Medical Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 50 | Netherlands |